Evaluation of surufatinib, an orally available VEGFR, FGFR1 and CSF-1R inhibitor, in combination with immune checkpoint blockade or chemotherapy in preclinical tumor models
Keyword(s):
Keyword(s):
2021 ◽
Keyword(s):
2020 ◽
Keyword(s):
Keyword(s):